Titlebook: Biologics to Treat Substance Use Disorders; Vaccines, Monoclonal Ivan D. Montoya Book 2016 Springer International Publishing Switzerland 20

輕快走過

https://doi.org/10.1007/978-3-540-71408-8d Manufacturing Practices (GMP). This chapter describes the self-assembling nanoparticle-based vaccines or synthetic vaccine particle (SVP) technology to induce antibodies against nicotine and potentially treat nicotine dependence.

錯(cuò)誤

Cocaine Hydrolases Designed from Butyrylcholinesterase

縱火

Introduction: Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzyn and Li 2012; Winchell et al. 2012; Donovan et al. 2012), low medication compliance during the conduct of clinical trials (Anderson et al. 2012, 2014; Somoza et al. 2013), and, with few exceptions, the perception by pharma that developing medications to treat SUDs will not provide a favorable retur

GEAR

Therapeutic Vaccines for Treating Nicotine Addictionr the pharmacokinetics (PK) of nicotine, slowing and reducing its entry into the brain and attenuating its reinforcing effects by binding nicotine in the blood (Gorelick, Future Med Chem 4(2):227–243, 2012). Extensive preclinical and clinical research has been conducted on nicotine conjugate vaccine

Prologue

Vaccines for Treating Cocaine Use Disordersbodies as catalysts for the metabolism of cocaine, researchers produced antibodies against the cocaine itself in human subjects..This cocaine vaccine now has been through late phase II clinical trials. The mechanism of action for this vaccine is to induce antibodies to the cocaine, which act kinetic

acetylcholine

Vaccines for Opioid Addictionr slowing their distribution to the brain, and attenuating addiction-relevant behaviors including heroin self-administration and reinstatement. The antibodies elicited by vaccines directed at heroin and its metabolites do not appreciably cross-react with methadone, buprenorphine, or naltrexone and s

SCORE

Cocaine and HIV Infection al. 2009), highlighting the extreme complexity of the overlapping epidemiologic landscape of cocaine use and HIV infection in the United States. The recent availability of the first prototypes of HIV and cocaine vaccines raises the question of the impact of these biological/medicinal interventions

流逝

一大群

Enzyme-Based Cocaine Pharmacotherapies: Current Status and Projections for the Future make this enzyme useful for most cocaine abusers. Pharmacological and behavioral procedures for evaluation of compounds of interest exist at both the preclinical and clinical levels. Discovery technology is making great strides toward the development of long-lasting enzyme therapeutics.

Hippocampus

Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders vaccine platform using cocaine and nicotine targets. Summaries are provided of the supporting data for efficacy in mice, rats, and non-human primates with phenotypes that include drug biodistribution, drug-induced locomotor behavior, drug self-administration, and positron emission tomography of dru